Creatine May Boost Cancer-Fighting Immune Cells, UCLA Study Suggests

Creatine has long been the gym-goer's supplement of choice—a way to pack more energy into muscle cells by boosting adenosine triphosphate, the currency of cellular power. But researchers at UCLA have just discovered it may do something far more consequential: help the immune system fight cancer more effectively.

The finding, published in iScience, builds on earlier work showing that creatine can supercharge killer T cells, the body's frontline cancer fighters. What's new is the recognition that creatine also fuels dendritic cells—the support network that identifies tumor fragments and directs T cells into battle. These dendritic cells are the generals; the T cells are the soldiers. Without good generals, even the best soldiers struggle.

The implications are significant. Current cancer immunotherapies, which train the immune system to recognize and destroy malignant cells, work in only 20 to 40 percent of patients. If creatine can energize the entire immune infrastructure supporting these treatments, it could shift those odds substantially. "What this study shows is that creatine doesn't just help the T cells fighting cancer—it also energizes the entire infrastructure that supports and guides them," says immunologist Lili Yang. "That makes creatine a promising supplement to holistically support the immune response that modern immunotherapies depend on."

The UCLA team started by examining tumors in mice, looking for which nutrient-related genes were most active in dendritic cells. They found that the creatine transporter—the cellular doorway through which creatine enters—was far more active in tumor-dwelling dendritic cells than in those from healthy tissue. When researchers grew dendritic cells in the lab without this transporter, the cells died faster and proved less effective at activating T cells. The T cells themselves, starved of this support, weakened in turn. Then the researchers tried the opposite: they boosted creatine in melanoma-bearing mice. Tumor growth slowed noticeably. Dendritic cell numbers and activity both increased.

The evidence so far comes only from mouse models and human cells grown in laboratory dishes. No one has yet tested whether creatine supplementation helps cancer patients receiving immunotherapy. That's the next frontier. The researchers plan to run clinical trials with people already undergoing immunotherapy, testing various creatine doses to see what effect, if any, it produces. "Understanding how to metabolically support dendritic cells is about supporting the entire anti-tumor response, not just the killer T cells at the end of it," says molecular biologist Elliot Kang.

The appeal of creatine as a potential therapeutic tool is practical. It's cheap to manufacture, widely available, and already used to treat people with rare metabolic disorders. It's generally considered safe at standard supplement doses, though individual health profiles matter. The researchers are emphatic: cancer patients should not start taking creatine on their own. Any such decision requires a doctor's guidance.

But if human trials confirm what the mouse studies suggest, the impact could be substantial. Creatine might work in two ways—as a supplement to strengthen the immune response in patients already receiving immunotherapy, and as a tool to improve dendritic cell quality before those cells are used in vaccine-based treatments. The path from laboratory discovery to clinical reality is long and uncertain. But for patients whose current immunotherapies fail, even a modest improvement in those odds would matter enormously.